-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In less than two weeks since the start of 2022, at least 9 senior executives of pharmaceutical companies in the pharmaceutical industry have changed, including positions such as president, vice president, and deputy general manager
.
On January 10, Dong'e Ejiao issued the "Announcement on the Resignation of the Chairman", announcing that Han Yuewei had applied to resign as chairman and director of the tenth session of the board of directors due to job changes, and also resigned as chairman of the strategy committee of the tenth session of the board of directors.
.
On the same day, Dong’e Ejiao announced that Gao Dengfeng had applied for his resignation as the president and legal representative of Dong’e Ejiao.
The reason for his resignation was due to changes in job content
.
From January 5 to January 6, a number of pharmaceutical companies released news of executive changes
.
Among them, on January 6, Sinopharm issued an announcement stating that Zhu Lin no longer served as secretary of the company's board of directors and deputy general manager of the company due to personal reasons
.
During his 16 years of working in Sinopharm, Zhu Lin has served as the director of the company's office, director of the securities department, secretary of the board of directors, deputy general manager and chairman of the subsidiary, director, supervisor and other positions
.
On the 6th, Shengxiang Bio announced that the board of directors recently received a written resignation report from the company's deputy general manager Gui Yaokui.
Gui Yaokui applied for his resignation as the company's deputy general manager for personal reasons, and will no longer hold any positions in the company after resignation; Buchang Pharmaceutical also announced that Liu Luxiang applied for his resignation as vice president of the company due to personal reasons, and will not hold any positions in the company after resignation; in addition, Jun Shengtai announced that Dr.
Chen Jin was appointed as senior vice president of pharmacokinetics and clinical pharmacology
.
It is understood that before joining Novartis, Dr.
Chen Jin also served as a clinical pharmacokinetic scientist at Amgen in the United States
.
On January 5, Sunflower Pharmaceutical announced that the company decided to appoint Zhou Guangguang as the secretary of the company's board of directors, and the term of office will expire at the end of the current board of directors; on the same day, Luoxin Pharmaceutical Chairman and CEO Liu Zhenteng, Executive Vice President and Chief Operating Officer Dong Li Jun announced to employees that from January 4, 2022, Wang Dong will be the CEO of Luoxin Health, responsible for the strategic planning and management of Luoxin Health; at the same time, he will also serve as the senior vice president of Luoxin Pharmaceutical's direct business business, responsible for the overall responsibility Luoxin Pharmaceutical's direct business management matters
.
On January 4, Bloomage Bio announced that the board of directors recently received a written resignation report from Li Huiliang, the company's deputy general manager, chief technology officer, and core technician.
He resigned from the company's deputy general manager and chief technology officer due to personal reasons.
No longer as a core technician, he will no longer hold any positions in the company and its subsidiaries after resignation
.
On January 3, Huahai Pharmaceutical issued an announcement stating that the board of directors recently received the resignation document of Wang Jie, the vice president of the company.
Since receiving the resignation document, Wang Jie will no longer hold any positions in the company, and his resignation will not affect the normal operation of the company.
run
.
It is understood that Wang Jie has held this position in the company since May 21, 2019
.
On January 3, Gan & Lee Pharmaceuticals announced that Dr.
Mike Hu was appointed as the CEO and general manager of Gan & Lee USA, leading and responsible for the global clinical development and management of the US subsidiary of Gan & Lee Pharmaceuticals
.
The announcement shows that Dr.
Mike Hu has a Ph.
D.
in Pharmacy from Shenyang Pharmaceutical University and completed postdoctoral research at Yale University School of Medicine.
Over 20 years of industry experience in approval
.
Judging from the reasons for the resignation and changes of the above-mentioned executives, it is mainly related to job changes and personal reasons
.
It can be seen that behind the frequent changes of senior executives of pharmaceutical companies, the pattern of the pharmaceutical industry is constantly changing
.
.
On January 10, Dong'e Ejiao issued the "Announcement on the Resignation of the Chairman", announcing that Han Yuewei had applied to resign as chairman and director of the tenth session of the board of directors due to job changes, and also resigned as chairman of the strategy committee of the tenth session of the board of directors.
.
On the same day, Dong’e Ejiao announced that Gao Dengfeng had applied for his resignation as the president and legal representative of Dong’e Ejiao.
The reason for his resignation was due to changes in job content
.
From January 5 to January 6, a number of pharmaceutical companies released news of executive changes
.
Among them, on January 6, Sinopharm issued an announcement stating that Zhu Lin no longer served as secretary of the company's board of directors and deputy general manager of the company due to personal reasons
.
During his 16 years of working in Sinopharm, Zhu Lin has served as the director of the company's office, director of the securities department, secretary of the board of directors, deputy general manager and chairman of the subsidiary, director, supervisor and other positions
.
On the 6th, Shengxiang Bio announced that the board of directors recently received a written resignation report from the company's deputy general manager Gui Yaokui.
Gui Yaokui applied for his resignation as the company's deputy general manager for personal reasons, and will no longer hold any positions in the company after resignation; Buchang Pharmaceutical also announced that Liu Luxiang applied for his resignation as vice president of the company due to personal reasons, and will not hold any positions in the company after resignation; in addition, Jun Shengtai announced that Dr.
Chen Jin was appointed as senior vice president of pharmacokinetics and clinical pharmacology
.
It is understood that before joining Novartis, Dr.
Chen Jin also served as a clinical pharmacokinetic scientist at Amgen in the United States
.
On January 5, Sunflower Pharmaceutical announced that the company decided to appoint Zhou Guangguang as the secretary of the company's board of directors, and the term of office will expire at the end of the current board of directors; on the same day, Luoxin Pharmaceutical Chairman and CEO Liu Zhenteng, Executive Vice President and Chief Operating Officer Dong Li Jun announced to employees that from January 4, 2022, Wang Dong will be the CEO of Luoxin Health, responsible for the strategic planning and management of Luoxin Health; at the same time, he will also serve as the senior vice president of Luoxin Pharmaceutical's direct business business, responsible for the overall responsibility Luoxin Pharmaceutical's direct business management matters
.
On January 4, Bloomage Bio announced that the board of directors recently received a written resignation report from Li Huiliang, the company's deputy general manager, chief technology officer, and core technician.
He resigned from the company's deputy general manager and chief technology officer due to personal reasons.
No longer as a core technician, he will no longer hold any positions in the company and its subsidiaries after resignation
.
On January 3, Huahai Pharmaceutical issued an announcement stating that the board of directors recently received the resignation document of Wang Jie, the vice president of the company.
Since receiving the resignation document, Wang Jie will no longer hold any positions in the company, and his resignation will not affect the normal operation of the company.
run
.
It is understood that Wang Jie has held this position in the company since May 21, 2019
.
On January 3, Gan & Lee Pharmaceuticals announced that Dr.
Mike Hu was appointed as the CEO and general manager of Gan & Lee USA, leading and responsible for the global clinical development and management of the US subsidiary of Gan & Lee Pharmaceuticals
.
The announcement shows that Dr.
Mike Hu has a Ph.
D.
in Pharmacy from Shenyang Pharmaceutical University and completed postdoctoral research at Yale University School of Medicine.
Over 20 years of industry experience in approval
.
Judging from the reasons for the resignation and changes of the above-mentioned executives, it is mainly related to job changes and personal reasons
.
It can be seen that behind the frequent changes of senior executives of pharmaceutical companies, the pattern of the pharmaceutical industry is constantly changing
.
